547 related articles for article (PubMed ID: 12553627)
1. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
4. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
5. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
6. Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
[No Abstract] [Full Text] [Related]
7. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
Langley RG; Gupta AK; Cherman AM; Inniss KA
J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
[TBL] [Abstract][Full Text] [Related]
8. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
Saini R; Tutrone WD; Weinberg JM
Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
[TBL] [Abstract][Full Text] [Related]
9. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
10. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
Tan X; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
[TBL] [Abstract][Full Text] [Related]
11. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
Tutrone WD; Saini R; Weinberg JM
IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
[TBL] [Abstract][Full Text] [Related]
12. Biological agents in the treatment of psoriasis.
Tzu J; Krulig E; Cardenas V; Kerdel FA
G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
[TBL] [Abstract][Full Text] [Related]
13. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
14. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
15. Biological therapy for psoriasis.
Clements SE; Abdul-Ghaffar S; Griffiths CE
Br J Hosp Med (Lond); 2006 Apr; 67(4):184-7. PubMed ID: 16681304
[No Abstract] [Full Text] [Related]
16. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
[TBL] [Abstract][Full Text] [Related]
18. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
19. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
Sauder DN; Mamelak AJ
J Cutan Med Surg; 2004; 8(4):205-12. PubMed ID: 16091996
[TBL] [Abstract][Full Text] [Related]
20. [Biologic therapy and psoriasis].
Gamo R; López-Estebaranz JL
Actas Dermosifiliogr; 2006; 97(1):1-17. PubMed ID: 16540046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]